



The Buoniconti Fund to Cure Paralysis, Inc.

Financial Statements
May 31, 2026

C O N T E N T S

INDEPENDENT AUDITOR'S REPORT	1 - 2
FINANCIAL STATEMENTS	
Statement of Financial Position	3
Statement of Activities	4
Statement of Functional Expenses	5
Statement of Cash Flows	6
Notes to Financial Statements	7 - 15

INDEPENDENT AUDITOR'S REPORT

The Buoniconti Fund to Cure Paralysis, Inc.
Miami, Florida

Opinion

We have audited the accompanying financial statements of The Buoniconti Fund to Cure Paralysis, Inc., which comprise the statement of financial position as of May 31, 2026, and the related statements of activities, functional expenses and cash flows for the year then ended, and the related notes to the financial statements.

In our opinion, the financial statements referred to above present fairly, in all material respects, the financial position of The Buoniconti Fund to Cure Paralysis, Inc. as of May 31, 2026, and the changes in its net assets and its cash flows for the year then ended in accordance with accounting principles generally accepted in the United States of America.

Basis for Opinion

We conducted our audit in accordance with auditing standards generally accepted in the United States of America. Our responsibilities under those standards are further described in the *Auditor's Responsibilities for the Audit of the Financial Statements* section of our report. We are required to be independent of The Buoniconti Fund to Cure Paralysis, Inc. and to meet our other ethical responsibilities, in accordance with the relevant ethical requirements relating to our audit. We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our audit opinion.

Responsibilities of Management for the Financial Statements

Management is responsible for the preparation and fair presentation of the financial statements in accordance with accounting principles generally accepted in the United States of America, and for the design, implementation, and maintenance of internal control relevant to the preparation and fair presentation of financial statements that are free from material misstatement, whether due to fraud or error.

In preparing the financial statements, management is required to evaluate whether there are conditions or events, considered in the aggregate, that raise substantial doubt about The Buoniconti Fund to Cure Paralysis, Inc.'s ability to continue as a going concern within one year after the date that the financial statements are available to be issued.


Auditor's Responsibilities for the Audit of the Financial Statements

Our objectives are to obtain reasonable assurance about whether the financial statements as a whole are free from material misstatement, whether due to fraud or error, and to issue an auditor's report that includes our opinion. Reasonable assurance is a high level of assurance but is not absolute assurance and therefore is not a guarantee that an audit conducted in accordance with generally accepted auditing standards will always detect a material misstatement when it exists. The risk of not detecting a material misstatement resulting from fraud is higher than for one resulting from error, as fraud may involve collusion, forgery, intentional omissions, misrepresentations, or the override of internal control. Misstatements are considered material if there is a substantial likelihood that, individually or in the aggregate, they would influence the judgment made by a reasonable user based on these financial statements.

In performing an audit in accordance with generally accepted auditing standards, we:

- Exercise professional judgment and maintain professional skepticism throughout the audit.
- Identify and assess the risks of material misstatement of the financial statements, whether due to fraud or error, and design and perform audit procedures responsive to those risks. Such procedures include examining, on a test basis, evidence regarding the amounts and disclosures in the financial statements.
- Obtain an understanding of internal control relevant to the audit in order to design audit procedures that are appropriate in the circumstances, but not for the purpose of expressing an opinion on the effectiveness of The Buoniconti Fund to Cure Paralysis, Inc.'s internal control. Accordingly, no such opinion is expressed.
- Evaluate the appropriateness of accounting policies used and the reasonableness of significant accounting estimates made by management, as well as evaluate the overall presentation of the financial statements.
- Conclude whether, in our judgment, there are conditions or events, considered in the aggregate, that raise substantial doubt about The Buoniconti Fund to Cure Paralysis, Inc.'s ability to continue as a going concern for a reasonable period of time.

We are required to communicate with those charged with governance regarding, among other matters, the planned scope and timing of the audit, significant audit findings, and certain internal control related matters that we identified during the audit.



Kaufman, Rossin & Co., P.A.

October 7, 2026
Miami, Florida

THE BUONICONTI FUND TO CURE PARALYSIS, INC.
STATEMENT OF FINANCIAL POSITION
MAY 31, 2026

ASSETS

CURRENT ASSETS

Cash and cash equivalents	\$	5,830,611
Pledges receivable, net (Note 2)		1,272,740
Inventory		76,632
Prepaid expenses and other current assets		88,198

TOTAL ASSETS	\$	7,268,181
--------------	----	-----------

LIABILITIES AND NET ASSETS

CURRENT LIABILITIES

Accounts payable and accrued expenses	\$	45,340
Deferred revenue		257,950
Total current liabilities		303,290

CONTINGENCIES (NOTE 8)

NET ASSETS

Without donor restrictions		3,127,467
With donor restrictions (Note 5)		3,837,424
Total net assets		6,964,891

TOTAL LIABILITIES AND NET ASSETS	\$	7,268,181
----------------------------------	----	-----------

See accompanying notes to the financial statements.

THE BUONICONTI FUND TO CURE PARALYSIS, INC.
STATEMENT OF ACTIVITIES
YEAR ENDED MAY 31, 2026

	Net assets without donor restrictions	Net assets with donor restrictions	Total
EVENT REVENUES, PUBLIC SUPPORT AND OTHER INCOME			
Gross event revenues and public support:			
Contributions	\$ 5,774,965	\$ 3,625,174	\$ 9,400,139
Ticket sales	404,250	-	404,250
Auction proceeds	625,048	-	625,048
In-kind contributions	89,666	-	89,666
Total gross event revenues and public support	6,893,929	3,625,174	10,519,103
Reductions of gross event revenues and public support:			
Auction cost of sales	(333,391)	-	(333,391)
Direct event costs	(1,652,997)	-	(1,652,997)
Total reductions of gross event revenues and public support	(1,986,388)	-	(1,986,388)
Total event revenues and public support	4,907,541	3,625,174	8,532,715
Other income:			
Interest	4,051	-	4,051
Amortization of discounts on pledges receivable	81,186	1,314	82,500
Total other income	85,237	1,314	86,551
Total event revenues, public support and other income	4,992,778	3,626,488	8,619,266
EXPENSES			
Program services	4,706,658	-	4,706,658
Supporting services	278,766	-	278,766
Total expenses	4,985,424	-	4,985,424
NET ASSETS RELEASED FROM RESTRICTIONS	520,250	(520,250)	-
CHANGE IN NET ASSETS	527,604	3,106,238	3,633,842
NET ASSETS - BEGINNING OF YEAR	2,599,863	731,186	3,331,049
NET ASSETS - END OF YEAR	\$ 3,127,467	\$ 3,837,424	\$ 6,964,891

See accompanying notes to the financial statements.

THE BUONICONTI FUND TO CURE PARALYSIS, INC.
STATEMENT OF FUNCTIONAL EXPENSES
YEAR ENDED MAY 31, 2026

	Program services			Supporting services			
	Contributions to The Miami Project	Awareness programs	Program services	Fundraising	Administrative and general	Supporting services	Total
Contributions to Miami Project	\$ 3,725,000	\$ -	\$ 3,725,000	\$ -	\$ -	\$ -	\$ 3,725,000
Awards and gifts	-	78	78	3,707	1,015	4,722	4,800
Bad debt recovery	-	-	-	(200,000)	-	(200,000)	(200,000)
Bank service charges	-	-	-	581	7,416	7,997	7,997
Equipment rental	-	-	-	-	437	437	437
Food and beverage	-	457	457	2,426	3,512	5,938	6,395
Insurance	-	-	-	-	26,451	26,451	26,451
Other	-	17,351	17,351	15,000	4,316	19,316	36,667
Venue - AV, photo, digital wifi & video	-	25,000	25,000	-	-	-	25,000
Postage	-	26	26	138	1,265	1,403	1,429
Printing	-	-	-	-	533	533	533
Professional services	-	372,790	372,790	91,733	64,682	156,415	529,205
Public relations	-	385,450	385,450	-	-	-	385,450
Salaries and fringe benefits	-	122,851	122,851	115,334	108,587	223,921	346,772
Supplies	-	3,815	3,815	2,853	15,610	18,463	22,278
Travel and entertainment	-	1,380	1,380	1,816	823	2,639	4,019
Telephone and utilities	-	-	-	-	10,531	10,531	10,531
Wheelchairs	-	52,460	52,460	-	-	-	52,460
	\$ 3,725,000	\$ 981,658	\$ 4,706,658	\$ 33,588	\$ 245,178	\$ 278,766	\$ 4,985,424

See accompanying notes to the financial statements.

THE BUONICONTI FUND TO CURE PARALYSIS, INC.
STATEMENT OF CASH FLOWS
YEAR ENDED MAY 31, 2026

CASH FLOWS FROM OPERATING ACTIVITIES:

Change in net assets	\$	3,633,842
Adjustments to reconcile change in net assets to net cash provided by operating activities:		
Bad debt recovery	(	200,000)
Amortization of discounts on pledges receivable	(	82,500)
Changes in operating assets and liabilities:		
Pledges receivable		699,052
Inventory		1,266
Prepaid expenses and other current assets		27,734
Accounts payable and accrued expenses		32,809
Deferred revenue	(	195,915)
Total adjustments		282,446
Net cash provided by operating activities, representing net change in cash and cash equivalents		3,916,288
CASH - BEGINNING		1,914,323
CASH AND CASH EQUIVALENTS - ENDING	\$	5,830,611

Supplemental Disclosure of Cash Flow Information:

Interest paid	\$	-
Income taxes paid	\$	-

See accompanying notes to the financial statements.

THE BUONICONTI FUND TO CURE PARALYSIS, INC.
NOTES TO FINANCIAL STATEMENTS
YEAR ENDED MAY 31, 2026

NOTE 1. NATURE OF ACTIVITIES AND SIGNIFICANT ACCOUNTING POLICIES

Nature of Activities

The Buoniconti Fund to Cure Paralysis, Inc. (the “Fund”) is a not-for-profit organization incorporated under the laws of the State of Florida for the purpose of raising funds and promoting national awareness for The Miami Project to Cure Paralysis (“The Miami Project”), at the University of Miami School of Medicine. The Miami Project is a research center devoted to raise awareness and funds to support and fund research and programs dedicated to discovering, developing, and advancing treatments and cures for neurological diseases and disorders, including but not limited to, traumatic spinal cord and brain injuries, peripheral nerve injuries, Alzheimer’s disease, Parkinson’s disease, Amyotrophic Later Sclerosis (“ALS”), Multiple Sclerosis (“MS”), and stroke.

Basis of Presentation

The financial statements of the Fund are prepared on the accrual basis of accounting in accordance with accounting principles generally accepted in the United States of America. Net assets, event revenues, public support, and other income are classified based on the existence or absence of donor-imposed restrictions as follows:

- ◆ *Net Assets Without Donor Restrictions* - Amounts that are not subject to usage restrictions based on donor-imposed requirements. This class also includes assets previously restricted where restrictions have expired or been met.
- ◆ *Net Assets with Donor Restrictions* - Amounts subject to usage limitations based on donor-imposed restrictions. These restrictions may be temporary or may be based on a particular use. Restrictions may be met by passage of time, be fulfilled, or removed by actions of the Fund, pursuant to those stipulations. Certain restrictions may need to be maintained in perpetuity.

Revenue Recognition - Contributions, Donated Services and In-Kind Contributions

Contributions, including unconditional promises, are accounted for under Accounting Standards Codification (“ASC”) 958-605, *Not-for-Profit Entities - Revenue Recognition*, and are recognized as revenue when the donor's commitment is received. Contributions are considered to be available for unrestricted use unless specifically restricted by the donor. Amounts received that are designated for future periods or restricted by the donor for specific purposes are reported as net assets with donor restrictions. When a temporary restriction expires, net assets with donor restrictions are reclassified to net assets without donor restrictions and reported in the statement of activities as net assets released from restrictions.

THE BUONICONTI FUND TO CURE PARALYSIS, INC.
NOTES TO FINANCIAL STATEMENTS
YEAR ENDED MAY 31, 2026

NOTE 1. NATURE OF ACTIVITIES AND SIGNIFICANT ACCOUNTING POLICIES
(Continued)

Revenue Recognition - Contributions, Donated Services and In-Kind Contributions
(continued)

The Fund utilizes in-kind contributions of nonfinancial assets to carry out its mission and records the value of these nonfinancial assets when there is an objective basis available to measure their value. For the year ended May 31, 2026, the estimated value of in-kind contributions approximated \$90,000.

For the year ended May 31, 2026, contributions from one donor accounted for approximately 34% of total gross event revenues and public support.

Revenue Recognition - Exchange Transactions

The Fund recognizes revenue from exchange transactions in accordance with Financial Accounting Standards Board ("FASB") Accounting Standards Update ("ASU") No. 2014-09, *Revenue from Contracts with Customers (Topic 606)* ("ASC 606"). Revenue is recognized pursuant to a five-step model: (i) identify contract(s) with the customer; (ii) identify the performance obligation in the contract; (iii) determine the transaction price; (iv) allocate the transaction price to the performance obligations; (v) recognize revenue when (or as) each performance obligation is satisfied. Under ASC 606, revenue is recognized when a customer obtains control of promised goods or services in an amount that reflects the consideration the Fund expects to receive in exchange for those goods or services. In addition, ASC 606 requires disclosure of the nature, amount, timing and uncertainty of revenue and cash flows arising from contracts with customers.

The Fund's sources of revenue from exchange transactions subject to ASC 606 include ticket sales and auction proceeds. Ticket sales are recognized at a point in time when the event occurs. Auction proceeds are recognized at a point in time when control of the auctioned item transfers to the purchaser.

Cash and Cash Equivalents

The Fund considers all highly liquid investments with original purchased maturities of three months or less to be cash equivalents. For the purpose of the statement of cash flows, cash and cash equivalents consists of monies held in a checking account and a U.S. Treasury money market fund. Cash and cash equivalents includes amounts with donor restrictions totaling approximately \$3,542,000 as of May 31, 2026.

THE BUONICONTI FUND TO CURE PARALYSIS, INC.
NOTES TO FINANCIAL STATEMENTS
YEAR ENDED MAY 31, 2026

NOTE 1. NATURE OF ACTIVITIES AND SIGNIFICANT ACCOUNTING POLICIES
(Continued)

Concentrations of Credit Risk

The Fund deposits excess cash with high-credit quality institutions. At times, such balances may be in excess of federally insured limits. As of May 31, 2026, the Fund had approximately \$1,642,000 of cash and cash equivalents in excess of the federally insured limit amount of \$250,000. Additionally, as of May 31, 2026, the Fund had approximately \$4,004,000 of cash and cash equivalents held in United States Treasury money market funds which are not federally insured.

Pledges Receivable

Unconditional pledges receivable are recognized at the time when the respective donor makes the promise. Unconditional pledges receivable due in the next year are recorded at their net realizable value, which is considered a reasonable estimate of fair value. Unconditional pledges receivable that are expected to be collected in future years are recognized at fair value, using present value techniques and applicable discount rates. The discounts on the estimated future cash flows of pledges receivable are computed using risk-free interest rates applicable to the respective years in which pledges are expected to be received. Conditional pledges receivable are recognized when the conditions on which they depend are substantially met, that is, when the conditional promise becomes unconditional.

An allowance for uncollectible pledges receivable is provided based upon management's judgment, including such factors as prior collection history, type of contribution, nature of fundraising activity, and current economic conditions. Pledges receivable are charged off against the allowance after all means of collection have been exhausted and the potential for recovery is considered remote. As of May 31, 2026, management has not recorded an allowance for uncollectible pledges.

At May 31, 2026, pledges receivable from three donors accounted for approximately 76% of total pledges receivable, net of discounts.

Inventory

Inventory consists primarily of auction items and event gifts stated at the lower of cost or net realizable value. Cost is determined by the first-in, first-out method.

THE BUONICONTI FUND TO CURE PARALYSIS, INC.
NOTES TO FINANCIAL STATEMENTS
YEAR ENDED MAY 31, 2026

NOTE 1. NATURE OF ACTIVITIES AND SIGNIFICANT ACCOUNTING POLICIES
(Continued)

Prepaid Expenses and Deferred Revenue

Prepaid expenses represent amounts paid in advance for special events to be held subsequent to year-end. Revenue from special event ticket sales received in advance for events is considered a customer contract liability and deferred until the period in which the event is held. The Fund considers the contribution portion of special event ticket sales to be conditional upon the event taking place; as such, it is recorded as deferred revenue along with the exchange portion of ticket sales. As of May 31, 2026 and 2025, deferred revenue amounted to approximately \$258,000 and \$454,000, respectively.

Advertising and Promotion

Advertising and promotion costs are expensed as incurred. For the year ended May 31, 2026, advertising and promotion expense amounted to approximately \$14,000 and is included in direct event costs in the accompanying statement of activities.

Functional Expenses

The Fund reports expenses by their functional classification. Expenses related directly to a program are charged to that program while indirect expenses are allocated principally on time and effort related to that function. The indirect costs of holding and administering the Fund's events and other activities have been summarized on a functional basis. Indirect event costs and other expenses are allocated by management to program and supporting services based on the percentage of employee time spent, among other factors. The allocation of costs on a functional basis is based on management's estimates.

Income Taxes

Income taxes are not provided for in the financial statements since the Fund is exempt from federal and state income taxes under Sections 501(c)(3) and 509(a)(1) of the Internal Revenue Code and similar state provisions. The Fund is not classified as a private foundation.

The Fund assesses its tax positions in accordance with "*Accounting for Uncertainties in Income Taxes*" as prescribed by the ASC, which provides guidance for financial statement recognition and measurement of uncertain tax positions taken or expected to be taken in a tax return for open tax years (generally a period of three years from the later of each return's due date or the date filed) that remain subject to examination by the Fund's major tax jurisdictions.

THE BUONICONTI FUND TO CURE PARALYSIS, INC.
NOTES TO FINANCIAL STATEMENTS
YEAR ENDED MAY 31, 2026

NOTE 1. NATURE OF ACTIVITIES AND SIGNIFICANT ACCOUNTING POLICIES
(Continued)

Income Taxes (continued)

The Fund assesses its tax positions and determines whether it has any material unrecognized liabilities for uncertain tax positions. The Fund records these liabilities to the extent it deems them more likely than not to be incurred. Interest and penalties related to uncertain tax positions, if any, would be classified as a component of income tax expense.

The Fund believes that it does not have any significant uncertain tax positions requiring recognition or measurement in the accompanying financial statements.

Use of Estimates in the Preparation of Financial Statements

The preparation of financial statements in conformity with accounting principles generally accepted in the United States of America requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities as of the statement of financial position date and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates.

Management's estimate of the net realizable value of its unconditional pledges receivable is based upon historical collection rates, analysis of the collectibility, and expected payment dates of individual pledges, valued using risk-free rates. This estimate may be subject to change as a result of potential amendments made to the terms of the individual pledges. Given the nature of this estimate, it is reasonably possible that the fair value of the Fund's pledges receivable could materially change in the near future.

THE BUONICONTI FUND TO CURE PARALYSIS, INC.
NOTES TO FINANCIAL STATEMENTS
YEAR ENDED MAY 31, 2026

NOTE 2. PLEDGES RECEIVABLE

At May 31, 2026, unconditional pledges receivable consisted of the following:

Current amounts due in:	
Less than one year	\$ 1,308,248
Less: unamortized discount	(35,508)
Total pledges receivable, net	\$ 1,272,740

The interest rate used in calculating discounts on the present value of estimated future cash flows ranges between 2.25% and 6.57%.

As of May 31, 2026, gross unrestricted pledges receivable from members of the Board of Directors amounted to approximately \$100,000.

NOTE 3. CONTRIBUTIONS TO THE MIAMI PROJECT

In accordance with its specific purpose, the Fund, upon approval of its Board of Directors, makes periodic contributions to The Miami Project based on the availability of cash. The nature of the Fund's activities is such that in any given fiscal year, significant unconditional pledge receivables can be promised, yet the cash related to these receivables is not collected until subsequent fiscal years. As a consequence, the Fund can have large fluctuations in its change in net assets and current activities from fiscal year-to-year, since the contributions to support The Miami Project are made at the discretion of the Fund's Board of Directors as the cash becomes available from the collection of its unconditional pledge receivables. During the year ended May 31, 2026, the Fund contributed \$3,725,000 in support of The Miami Project.

NOTE 4. RELATED PARTY TRANSACTIONS

Miami Project

Several of the Fund's officers and directors are employed by The Miami Project. The management and staff of The Miami Project are compensated by the University of Miami (the "University"). The Fund's Miami office is operated by The Miami Project and the University is responsible for all expenses related to the office. The value of the Fund's portion of these expenditures is not considered significant to the financial statements.

THE BUONICONTI FUND TO CURE PARALYSIS, INC.
NOTES TO FINANCIAL STATEMENTS
YEAR ENDED MAY 31, 2026

NOTE 4. RELATED PARTY TRANSACTIONS (Continued)

Contributions and Other Support

During the year ended May 31, 2026, contributions and support from members of the Board of Directors amounted to approximately \$875,000.

NOTE 5. NET ASSETS

At May 31, 2026, net assets with donor restrictions were available for the following purposes:

Multipurpose communications laboratory	\$	500,000
Clinical programs/trials		345,174
The Paul J. DiMare ALS Research Fund		2,992,250
	\$	3,837,424

Multipurpose Communications Laboratory

The Miami Project is in the process of developing a multipurpose communications laboratory on the first floor of the Lois Pope Life Center. The facility will provide educational resources for graduate students and postdoctoral associates affiliated with The Miami Project. The laboratory will also serve as a dedicated space for scientific collaboration, interdisciplinary meetings, seminars, workshops, and related scholarly activities. Integration of advanced communication technologies and flexible meeting space is expected to support formal instruction and informal collaboration. The laboratory is intended to foster innovation and accelerate translational research.

Clinical Programs/Trials

The Miami Project develops clinical strategies to protect and repair the nervous system in individuals with spinal cord injuries and other neurological conditions. Current research initiatives include therapeutic hypothermia for acute spinal cord injuries, stem cell therapies under FDA-approved clinical trials, extracellular vesicles (exosomes) as alternatives to traditional cell transplantation, and neuromodulation and brain-computer interface programs to improve function.

These research programs are designed to advance treatment for paralysis and to improve outcomes in conditions including brain injuries, Alzheimer's disease, Parkinson's disease, ALS, MS, and stroke.

THE BUONICONTI FUND TO CURE PARALYSIS, INC.
NOTES TO FINANCIAL STATEMENTS
YEAR ENDED MAY 31, 2026

NOTE 5. NET ASSETS (Continued)

Clinical Programs/Trials (continued)

The Miami Project's rehabilitation/clinical facilities at the Christine E. Lynn Rehabilitation Center offer various clinical and rehabilitation programs for individuals with spinal cord injuries, including innovative clinical studies in motor function restoration, neuropathic pain management, and spasticity. The Center also supports brain-controlled neuromodulation therapy under the direction of Dr. Matija Milosevic and engages in collaborative initiatives with other leading clinical programs. These activities establish a platform for advancing neural repair and improving functional outcomes.

The Paul J. DiMare ALS Research Fund

The Fund was created in honor of Paul J. DiMare whose family provided funding to support ALS research. The Fund received this contribution designated to support a first-in-human Phase 1 clinical trial being conducted at The Miami Project. The clinical trial is evaluating the safety and preliminary efficacy of Schwann cell-derived exosomes (SCExo) in patients with ALS.

Treatment with SC-Exo is an investigational regenerative approach designed to deliver neurotrophic factors and signaling molecules that may support axonal repair and regeneration, reduce neuroinflammation, and promote neuronal survival. The clinical trial represents an effort to translate regenerative research into a potential therapeutic approach for individuals with ALS.

NOTE 6. LIQUIDITY

The Fund's financial assets as of May 31, 2026, that are available for general expenditure within one year of the statement of financial position date are as follows:

Total assets, at year-end	\$ 7,268,181
Less non-financial assets:	
Inventory	(76,632)
Prepaid expenses and other current assets	(88,198)
Total financial assets	7,103,351
Less financial assets unavailable for general expenditures within one year, due to:	
Cash restricted by donor with purpose restriction	(3,542,250)
Current portion of pledge receivable restricted by donor with purpose restriction	(295,174)
Financial assets available to meet cash needs for general expenditure within one year	\$ 3,265,927

THE BUONICONTI FUND TO CURE PARALYSIS, INC.
NOTES TO FINANCIAL STATEMENTS
YEAR ENDED MAY 31, 2026

NOTE 6. LIQUIDITY (Continued)

As part of the Fund's liquidity management, it has a policy to structure its financial assets to be available as its general expenditures, liabilities, and other obligations come due. The Fund considers all expenditures related to its ongoing activities to accomplish its mission as well as the conduct of services undertaken to support those activities to be general expenditures.

NOTE 7. CHAPTERS OF THE BUONICONTI FUND TO CURE PARALYSIS, INC.

The Fund has established committees ("Chapters") consisting of volunteers who seek to promote the national fundraising efforts of the Fund and The Miami Project by hosting events in their respective cities. As of May 31, 2026, there are eight active chapters throughout Florida, South Carolina, Indiana, Pennsylvania and California. Fundraising activities are coordinated by the staff of the Fund and revenues and expenses related to all such activities are included in the accompanying financial statements.

NOTE 8. CONTINGENCIES

Economic Conditions

The Fund depends on contributions and contributed services for its revenues. The ability of certain Fund donors to continue giving amounts comparable with prior years may be dependent upon current and future overall economic conditions and the continued deductibility for income tax purposes of contributions to the Fund. While the Fund's Board of Directors believes the Fund has the resources to continue its activities, its ability to do so and the extent to which it continues, may be dependent on the above factors.

Litigation

The Fund may be involved in various claims and legal actions arising in the ordinary course of activities. In the opinion of management, the ultimate disposition of these matters will not have a material adverse effect on the Fund's financial position or results of operations.

NOTE 9. SUBSEQUENT EVENTS

The Fund has evaluated subsequent events through October 7, 2026, which is the date the accompanying financial statements were available to be issued.